SlideShare a Scribd company logo
1 of 118
Prepared by
Padmaja V
Asst. Prof.
FCP, SBMCH
 Definition
 Etiology
 Types
 Pathophysiology/pathogenesis
 Signs and symptoms
 Diagnosis
 treatment
HYPERTENSION
 Definition - Hypertension refers to sustained elevation in
systemic arterial blood pressure.
 The elevation may be in either systolic or diastolic pressure, or
in both.
 A normal upper limit for an adult is 130–139/85–89 mmHg and
any readings consistently above this are considered as
hypertension.
 Normal – 120/80mmHg.
Types of hypertension
 Primary or essential hypertension (90 %).
 Secondary hypertension (10%) where there is an underlying
cause, such as renal diseases or tumour of the adrenal medulla.
 Malignant hypertension occurs in the younger age groups with
renal and collagen diseases.
 Isolated systolic hypertension mainly occurs when a
combination of factors is seen in the elderly, and is due to
increases in cardiac output, increased peripheral resistance and
renal vascular resistance.
ETIOLOGY
 Although the cause or causes of primary hypertension is
unknown, several risk factors have been identified for its
development:
 obesity
 stress
 cigarette smoking and alcohol consumption
 excessive intake of sodium causing fluid retention
 family history.
 Secondary hypertension results from underlying causes such as:
 renal diseases
 Cushing’s syndrome
 hypo/hyperthyroidism
 oral contraceptives
 excessive alcohol consumption
 coarctation (narrowing) of the aorta.
PATHPHYSIOLOGY OF PRIMARY
HYPERTENSION
 Primary hypertension results from a combination of genetic and
environmental factors which have an effect on renal and vascular
functions.
 One of the possible causes of primary hypertension is a deficiency in
the kidney’s ability to excrete sodium, which increases extracellular
fluid volume and cardiac output, resulting in an increase in blood flow
to the tissues.
 The increased blood flow to the tissues results in arteriolar
constriction and an increase in peripheral vascular resistance (PVR)
and blood pressure
PATHPHYSIOLOGY OF PRIMARY
HYPERTENSION
PATHOPHYSIOLOGY OF SECONDARY
HYPERTENSION
 Secondary hypertension is caused by diseases of the organs
resulting in a raised PVR and increased cardiac output.
 In most cases, the focus is on kidney diseases or excessive
levels of hormones such as aldosterone and cortisol.
 These hormones stimulate the retention of sodium and water,
resulting in increased blood volume and blood pressure.
 Once the underlying cause is treated, such as with the removal
of the diseased organ, the blood pressure returns to normal.
MALIGNANT HYPERTENSION
 This is a rapidly progressive hypertension where the diastolic
pressure is in excess of 120 mmHg which can result in
encephalopathy, cerebral oedema and loss of consciousness.
 Malignant hypertension does not indicate that there is cellular injury,
but because it is life-threatening, it is considered as an emergency.
 If untreated, cerebral oedema and cerebral dysfunction occur,
leading to death of the individual.
 Malignant hypertension can cause a variety of complications, e.g.
papilloedema, cardiac failure, cerebrovascular accident and
retinopathy
ISOLATED SYSTOLIC HYPERTENSION
 This is caused by an increase in cardiac output or PVR and has a
higher incidence in the elderly.
 The rigidity of the vessels is often caused by atherosclerosis.
 The ageing process leads to hardening of the arteries, increased PVR
and decreased baroreceptor sensitivity.
 In isolated systolic hypertension, the systolic blood pressure is over
140 mmHg and the diastolic pressure is less than 90 mmHg.
 It is recognised as an important risk factor for cerebrovascular
accident and cardiac failure, and thus should be treated as a medical
emergency.
SIGNS AND SYMPTOMS
TREATMENT
 Non-pharmacological interventions
 Advise the patient to restrict sodium intake
 cessation of cigarette smoking and excessive alcohol consumption
reduce their stress levels .
 Exercise and maintenance of a healthy weight
 Pharmacological interventions
 Diuretics are prescribed to reduce fluid load, which leads to reduction
in cardiac output, thus helping to reduce blood pressure.
 Medications, e.g. beta-blockers, calcium channel blockers and
angiotensin-converting enzyme (ACE) inhibitors, are indicted for the
treatment of hypertension
HEART FAILURE
 Heart failure is a chronic, progressive condition in
which the heart muscle is unable to pump enough
blood to meet the body’s needs for blood and oxygen.
 Basically, the heart can’t keep up with its workload.
ETIOLOGY
 Heart failure may be caused by a variety of conditions:
 acute MI, where there is a loss of myocardial muscle, which
can lead to poor contraction
 hypertension
 valvular heart disease
 inadequate emptying from the left ventricle due to poor
contraction of the myocardium
 anaemia resulting from reduced red blood cells.
Left-sided heart failure
 In left-sided or left ventricular (LV) heart failure, the left
side of the heart does not pump the blood sufficiently or
work harder to pump the same amount of blood.
 There are two types of left-sided heart failure.
 Heart failure with reduced ejection fraction (HFrEF),
also called systolic failure: The left ventricle loses its
ability to contract normally. The heart can't pump with
enough force to push enough blood into circulation.
 Heart failure with preserved ejection fraction
(HFpEF), also called diastolic failure (or diastolic
dysfunction): The left ventricle loses its ability to relax
normally (because the muscle has become stiff). The
heart can't properly fill with blood during the resting
period between each beat.
Right-sided heart failure
 Right-sided or right ventricular (RV) heart failure usually occurs
as a result of left-sided failure.
 When the left ventricle fails, increased fluid pressure is, in effect,
transferred back through the lungs, ultimately damaging the
heart's right side.
 When the right side loses pumping power, blood backs up in the
body's veins.
 This usually causes swelling or congestion in the legs, ankles and
swelling within the abdomen such as the GI tract and liver
Congestive heart failure
 Blood flow out of the heart slows, blood returning to the
heart through the veins backs up, causing congestion in the
body's tissues.
 Often swelling (edema) results. Most often there's swelling
in the legs and ankles.
 Fluid collects in the lungs and interferes with breathing,
causing shortness of breath, especially when a person is
lying down. This is called pulmonary edema and if left
untreated can cause respiratory distress.
Pathophysiology
 The onset of HF may be acute or chronic. It is often associated
with systolic and diastolic congestion and with myocardial
weakness.
 This weakness impairs the ability of the heart to pump efficiently.
 In acute HF, there is a sudden decrease in the amount of blood
pumped out from both ventricles, which leads to a reduction in
oxygen supply to the tissues.
 However, in chronic HF the progression of the disease is gradual
and in the early stages there may be no symptoms of heart failure.
Pathophysiology of right heart failure
 RHF is associated with the right ventricle being unable to pump
the blood into the pulmonary artery leading into the lungs.
 This leads to an increase in volume of the right ventricle during
the end-diastolic phase, which causes an increase in volume of
the right atria.
 This in turn increases the volume of blood and pressure in the
systemic venous system.
 There is accumulation of blood in some of the major organs – the
liver, the kidneys and the spleen, resulting in enlargement of
these organs and their eventual destruction.
Pathophysiology of left heart failure
 LHF results from damage to the left ventricular myocardium.
 The contraction of the left ventricle is ineffective and it cannot
pump out all the blood it receives from the left atrium
 This results in pooling of blood in the left atrium and raised
pressure in the pulmonary veins, which leads to pulmonary
oedema.
 Failure of the left ventricle also results in poor cardiac output. As
the cardiac output decreases, perfusion to the tissues also
diminishes, resulting in poor delivery of oxygen and nutrients to
the tissues
TREATMENT
TREATMENT
 Non-pharmacological
 Moderate physical activity
 Weight reduction
 Reduction in salt intake
 Pharmacological
ANGINA
 Definition - Angina is chest pain that occurs when the heart
muscle does not receive enough oxygenated blood.
 It is also described as a crushing pain in the chest.
 The term is derived from a Latin word meaning to choke.
 The pain can radiate through to the back and shoulder, or down
one or both arms, or into the neck and jaw.
TYPES OF ANGINA
 There are three types of angina:
 1. stable angina
 2. unstable angina
 3. variant angina.
STABLE ANGINA
 Stable angina is the most common type and it occurs when
there is a greater demand on the heart than usual.
 Stable angina is mainly caused by myocardial ischemia.
 The pain usually lasts about 3–5 minutes. If the blood flow is
restored by immediate treatment, no permanent damage results
UNSTABLE ANGINA
 Unstable angina (also known as crescendo angina) is
characterised by a change in frequency, intensity and duration
of pain.
 It is more serious than stable angina and is unpredictable.
 It can also occur when the person is at rest and is not relieved
by rest or medication.
 Patients who develop unstable angina are at risk of having an
MI
VARIANT ANGINA
 Variant angina is a rare form of angina.
 It is thought to occur as a result of coronary artery vasospasm
resulting in diminished blood flow.
 Variant angina is very painful and occurs from midnight to
early morning.
 It usually occurs at rest and the same time each day
PATHOPHYSIOLOGY
 Angina results from a blockage in the coronary arteries, which
reduces blood supply to the affected part of the heart muscle.
 At rest the blood supply may be sufficient to provide nutrients
and oxygen to the heart muscle; however, during activity, e.g.
walking or running, the heart rate increases which puts more
effort on the heart.
 During exertion, if the blood flow to the heart muscle is
inadequate, the oxygen supply is also diminished, leading to
severe pain
SIGNS AND SYMPTOMS
TREATMENT
 Non-pharmacological interventions
 eat a healthy diet and avoid saturated fat
 encouraged to lose weight
 Avoid excessive alcohol and smoking
 blood pressure monitored regularly
 Pharmacological interventions
 GTN
 Aspirin
 Beta-blocker drugs
 Statin drugs
Myocardial infarction
 Myocardial infarction (MI) is commonly referred to as
a ’heart attack’, which results from oxygen starvation
of the myocardium.
 When the coronary blood flow is occluded as a result
of a blood clot or fatty deposits (atheromatous plaque)
over a period of time, death of the myocardium will
take place, resulting in MI
ETIOLOGY
 Abnormal lipid profile
 Diabetes mellitus
 Psychosocial factors such as depression, loss of
control, global stress, financial stress, and life events
including marital separation, job loss, and family
conflicts
 Lack of physical activity
PATHOPHYSIOLOGY
 An occluded coronary artery results in myocardial
ischaemia due to a lack of oxygen to the myocardial cells.
 If the heart tissue is deprived of oxygen for a prolonged
period of time, approximately 20–45 minutes, this can lead
to cell death (necrosis) distal to the occlusion.
 Damaged heart tissue conducts electrical signals much
more slowly than normal heart tissue, which can result in
inefficient contraction of the myocardium.
 This can result in decrease:
 volume of blood ejected by the left ventricle with each
heartbeat
 cardiac output (volume of blood pumped out by the
left ventricle each minute)
 blood pressure
 tissue perfusion.
Evaluation
 The three components in the evaluation of the MI are
 clinical features,
 ECG findings, and
 cardiac biomarkers
TREATMENT
TREATMENT
 Non Pharmacological
 Counseling and education of patients
 Smoking cessation and avoid alcohol intake
 Dietary control (low cholesterol)
 Exercise
 Weight reduction
ATHEROSCLEROSIS/ARTERIOSCLEROSIS
 Arteriosclerosis is the term describing arterial disorders in
which degenerative changes result in decreased blood flow.
 Atherosclerosis is the most common form of
arteriosclerosis where there is thickening and hardening of
the vessel walls due to lipid accumulation.
 This condition is found mainly in the large- and medium-
sized arteries, such as the aorta and its branches, the
coronary arteries and the arteries that supply the brain,
whereas arteriosclerosis mainly affects arterioles
ETIOLOGY
 The cause of atherosclerosis is not known, but certain risk factors have been
identified:
 Hypertension
 cigarette smoking (nicotine has a vasoconstricting eff ect)
 high lipid levels in the blood
 familial history
 obesity
 diabetes mellitus (high serum glucose levels cause vascular damage)
 lifestyle
 alcohol
 gender (men are at a higher risk than women).
PATHOPHYSIOLOGY
 Atherosclerosis is a form of arteriosclerosis where the walls
of the arteries are hard, thick and narrow as a result of lipid
accumulation within the arterial walls.
 Lipids (low-density lipoproteins [LDL]) are deposited on
the tunica intima of the damaged blood vessel where
oxidation of LDL takes place.
 The oxidised LDL then enters the tunica intima of the
arterial wall, where they are ingested by macrophages.
 The lipid-filled macrophages then become foam cells.
 Once the foam cells accumulate in significant numbers, they form
a lesion called a fatty streak, which over time causes a bulge in the
lumen of the blood vessel and this restricts blood flow.
 Affected blood vessels become hard, lose their elasticity, restrict
blood flow and eventually occlude the artery.
 Greater blood pressure is needed to push the blood through these
narrow blood vessels, which leads to hypertension.
 Although atherosclerosis can affect any organ or tissue, the
arteries supplying the heart, brain, small intestines, kidneys and
lower extremities are mostly affected.
BRONCHIAL ASTHMA
 Asthma is a disease of airways that is characterised by
increased responsiveness of the tracheobronchial tree to a
variety of stimuli resulting in widespread spasmodic narrowing
of the air passages which may be relieved spontaneously or by
therapy.
 Asthma is an episodic disease manifested clinically by
paroxysms of dyspnoea, cough and wheezing.
 Asthma is a chronic inflammatory disorder of the lungs
ETIOPATHOGENESIS AND TYPES
 Two broad etiologic types are traditionally described:
 extrinsic (allergic, atopic) asthma and
 intrinsic (idiosyncratic, non-atopic) asthma
1. EXTRINSIC (ATOPIC, ALLERGIC)
ASTHMA
 In extrinsic asthma, airway inflammation is a consequence of
hypersensitive reactions associated with allergy, i.e. pollen, dust mites
or foodstuffs
 It usually begins in childhood or in early adult life.
 Most patients of this type of asthma have personal and/or family
history of preceding allergic diseases such as rhinitis, urticaria or
infantile eczema.
 Hyper sensitivity to various extrinsic antigenic substances or
‘allergens’ is usually present in these cases.
 Most of these allergens cause ill effects by inhalation e.g.
house dust, pollens, animal danders, moulds etc.
 Occupational asthma stimulated by fumes, gases and organic
and chemical dusts is a variant of extrinsic asthma.
 There is increased level of IgE in the serum and positive skin
test with the specific off ending inhaled antigen representing
an IgE-mediated type I hypersensitivity reaction which
includes an ‘acute immediate response’ and a ‘late phase
reaction’
 Acute immediate response is initiated by IgE-sensitised mast
cells (tissue counterparts of circulating basophils) on the
mucosal surface.
 Mast cells on degranulation release mediators like histamine,
leukotrienes, prostaglandins, platelet activating factor and
chemotactic factors for eosinophils and neutrophils.
 The net effects of these mediators are bronchoconstriction,
oedema, mucus hypersecretion and accumulation of eosinophils
and neutrophils
 Late phase reaction follows the acute immediate response and
is responsible for the prolonged manifestations of asthma.
 It is caused by excessive mobilisation of blood leucocytes that
include basophils besides eosinophils and neutrophils.
 These result in further release of mediators which accentuate
the above-mentioned effects.
 2. Intrinsic (idiosyncratic, non-atopic) asthma
 Intrinsic asthma is linked to hyper-responsive reactions to other forms
of stimuli, e.g. infection, sudden exposure to cold, exercise, stress or
cigarette smoke
 This type of asthma develops later in adult life with negative personal
or family history of allergy, negative skin test and normal serum levels
of IgE.
 Most of these patients develop typical symptom complex after an
upper respiratory tract infection by viruses.
 Associated nasal polypi and chronic bronchitis are commonly present.
 There are no recognisable allergens but about 10% of patients become
hypersensitive to drugs, most notably to small doses of aspirin
(aspirin-sensitive asthma).
Pathophysiology
 The bronchi and bronchioles contain smooth muscle and are lined
with mucous-secreting glands and ciliated cells.
 Close to the airway’s blood supply, there are large quantities of mast
cells.
 Once stimulated, mast cells release a number of cytokines (chemical
messengers), which cause physiological changes to the lining of the
bronchi and bronchioles.
 Three such cytokines are histamine, kinins and prostaglandins, which
cause smooth muscle contraction, increased mucus production and
increased capillary permeability.
 The airways soon narrow and become flooded with mucus and
fluid leaking from blood vessels
 As the airways become obstructed, the patient finds it
increasingly hard to breathe and to cough up the mucus.
 If unresolved, fatigue can occur and the patient’s respiratory
effort becomes weak and inadequate, causing hypoxaemia and
in severe cases, hypercapnia.
SIGNS AND SYMPTOMS
TREATMENT
TREATMENT
COPD
 Chronic Obstructive Pulmonary Disease (COPD)
 Chronic obstructive pulmonary disease (COPD) is a
chronic inflammatory lung disease that causes
obstructed airflow from the lungs.
 Symptoms include breathing difficulty, cough, mucus
(sputum) production and wheezing.
 Obstructive bronchiolitis is a condition in which chronic
inflammation and swelling cause the inside of the breathing
tubes (airways) to be smaller than normal.
 Chronic bronchitis
 Chronic bronchitis irritates your bronchial tubes, which
carry air to and from your lungs. In response, the tubes
swell and mucus (phlegm or “snot”) builds up along the
lining.
 The buildup narrows the tube’s opening, making it hard to
get air into and out of your lungs.
 EMPHYSEMA
 This results from damage to your lungs’ air sacs
(alveoli) that destroys the walls inside them and
causes them to merge into one giant air sac. It can’t
absorb oxygen as well, so you get less oxygen in your
blood. Damaged alveoli can make your lungs stretch
out and lose their springiness. Air gets trapped in your
lungs and you can’t breathe it out, so you feel short of
breath.
ACUTE RENAL FAILURE
 DEFINITION - Acute kidney injury (AKI), previously
known as acute renal failure (ARF), is a condition in
which the kidneys are unable to remove accumulated
metabolites from the blood, leading to altered fluid,
electrolyte and acid–base balance.
 i.e acute fall in GFR, thus decreasing the clearance of
metabolic waste products.
TYPES
1.Prerenal
 Prerenal causes include insufficient blood flow to the
kidneys, resulting in reduced cardiac output as a result of
heart failure, hypovolemia resulting from haemorrhage and
shock.
 The kidneys receive 20–25% of cardiac output to maintain
glomerular filtration.
 With a reduction in renal blood flow, glomerular filtration
is affected and this causes ischaemic changes to the renal
tissues.
2. Intrarenal
 Intrarenal failure results from conditions that impair renal
function.
 The renal parenchyma and nephrons are damaged, leading
to renal failure.
 Glomerulonephritis, hypertension, chemicals such as ethyl
glycol and drugs, e.g. antibiotics, can all affect renal
function.
 The nephrons of the kidneys are susceptible to trauma from
poor renal blood flow, hypertension and shock.
 The cell membranes of the nephrons are damaged as a
result of the trauma.
 The renal tubules become blocked with debris, thus
increasing tubular pressure, resulting in poor elimination
of sodium, water and metabolic waste.
 Nephrotoxic drugs such as aminoglycoside antibiotics,
non-steroidal anti-inflammatory drugs and toxins from
bacteria destroy tubular cells.
 The damaged tubular cells become permeable to water,
sodium and metabolic waste.
 Post renal
 Post renal failure results from obstruction along the
ureters, urinary bladder and urethra.
 Obstruction resulting from stones in the ureters,
prostatic hyperplasia and urethral stricture could
restrict urine flow, leading to postrenal failure.
SIGNS AND SYMPTOMS
 Edema in lower extremities
 Uremic encephalopathy
 Ascites
 Mental confusion, restlessness
 Poor skin turgidity
 Postural hypotension
CHRONIC RENAL FAILURE
 DEFINITION - ) CRF is defined as the progressive
reduction in renal function over months to years.
 The condition is irreversible and eventually affects all
the organs of the body.
 The parenchyma and the nephrons are destroyed and
the renal function progressively diminishes.
 Etiology
 There are many causes for CKD
 renal disease such as polycystic disease
 arteriosclerosis
 chronic glomerulonephritis
 chronic pyelonephritis
 tuberculosis of the kidneys
 diabetes nephropathy
 hypertension
 renal calculi
 prostatic hypertrophy.
UNIT - II.pptx
UNIT - II.pptx
UNIT - II.pptx
UNIT - II.pptx
UNIT - II.pptx
UNIT - II.pptx
UNIT - II.pptx

More Related Content

Similar to UNIT - II.pptx

Circulatory diseases and disorders
Circulatory diseases and disordersCirculatory diseases and disorders
Circulatory diseases and disorders
Ronnie Z. Valenciano
 
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatment
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatmentIschemic heart disease (IHD) pathophysiology , types , its causes and treatment
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatment
Home
 
Pathophsyology left ventricular failure
Pathophsyology left ventricular failurePathophsyology left ventricular failure
Pathophsyology left ventricular failure
Keren Shay
 

Similar to UNIT - II.pptx (20)

Cardiac Failure, Cardiac Shock, Cardiac Arrest, PPT
Cardiac Failure, Cardiac Shock, Cardiac Arrest,  PPTCardiac Failure, Cardiac Shock, Cardiac Arrest,  PPT
Cardiac Failure, Cardiac Shock, Cardiac Arrest, PPT
 
Pathophysiology of Heart failure notes
Pathophysiology of Heart failure notesPathophysiology of Heart failure notes
Pathophysiology of Heart failure notes
 
cardiac medicine
cardiac medicinecardiac medicine
cardiac medicine
 
Blood pressure regulation
Blood pressure regulationBlood pressure regulation
Blood pressure regulation
 
Congestive heart failure
Congestive heart failureCongestive heart failure
Congestive heart failure
 
Cardio3
Cardio3Cardio3
Cardio3
 
Htn Heart Failure 2010
Htn Heart Failure 2010Htn Heart Failure 2010
Htn Heart Failure 2010
 
Htn Heart Failure 2010
Htn Heart Failure 2010Htn Heart Failure 2010
Htn Heart Failure 2010
 
symptomatic hypertension
symptomatic hypertensionsymptomatic hypertension
symptomatic hypertension
 
Circulatory diseases and disorders
Circulatory diseases and disordersCirculatory diseases and disorders
Circulatory diseases and disorders
 
Congestive cardiac failure
Congestive cardiac failureCongestive cardiac failure
Congestive cardiac failure
 
Cardiology Class
Cardiology ClassCardiology Class
Cardiology Class
 
Cardiac Function Tests.ppt
Cardiac Function Tests.pptCardiac Function Tests.ppt
Cardiac Function Tests.ppt
 
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatment
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatmentIschemic heart disease (IHD) pathophysiology , types , its causes and treatment
Ischemic heart disease (IHD) pathophysiology , types , its causes and treatment
 
Cardiac Failure Sem 5.pptx
Cardiac Failure Sem 5.pptxCardiac Failure Sem 5.pptx
Cardiac Failure Sem 5.pptx
 
A brief synopsis of acute decompensated heart failure
A brief synopsis of acute decompensated heart failureA brief synopsis of acute decompensated heart failure
A brief synopsis of acute decompensated heart failure
 
Pathophsyology left ventricular failure
Pathophsyology left ventricular failurePathophsyology left ventricular failure
Pathophsyology left ventricular failure
 
Tag training version 1.0
Tag training version 1.0Tag training version 1.0
Tag training version 1.0
 
Hypertension (HTN)
Hypertension (HTN)Hypertension (HTN)
Hypertension (HTN)
 
Aortic Stenosis
Aortic StenosisAortic Stenosis
Aortic Stenosis
 

More from Jane756411

MACROLIDE.pptxpharmacypharmacpharmacypharm
MACROLIDE.pptxpharmacypharmacpharmacypharmMACROLIDE.pptxpharmacypharmacpharmacypharm
MACROLIDE.pptxpharmacypharmacpharmacypharm
Jane756411
 
CAL software Hemaharshini.G.pptxsdggfasf
CAL software Hemaharshini.G.pptxsdggfasfCAL software Hemaharshini.G.pptxsdggfasf
CAL software Hemaharshini.G.pptxsdggfasf
Jane756411
 
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
Jane756411
 
37.Tidings (08.01.2024-13.01.2024)19.pptx
37.Tidings (08.01.2024-13.01.2024)19.pptx37.Tidings (08.01.2024-13.01.2024)19.pptx
37.Tidings (08.01.2024-13.01.2024)19.pptx
Jane756411
 
38.Tidings (15.01.2024-20.01..2024).pptx
38.Tidings (15.01.2024-20.01..2024).pptx38.Tidings (15.01.2024-20.01..2024).pptx
38.Tidings (15.01.2024-20.01..2024).pptx
Jane756411
 
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdfb0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
Jane756411
 
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
Jane756411
 
planttissueculturelaboratory-151212154641.pdf
planttissueculturelaboratory-151212154641.pdfplanttissueculturelaboratory-151212154641.pdf
planttissueculturelaboratory-151212154641.pdf
Jane756411
 
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
Jane756411
 
basicrequirementfortissueculture-190102180201.pdf
basicrequirementfortissueculture-190102180201.pdfbasicrequirementfortissueculture-190102180201.pdf
basicrequirementfortissueculture-190102180201.pdf
Jane756411
 

More from Jane756411 (20)

MACROLIDE.pptxpharmacypharmacpharmacypharm
MACROLIDE.pptxpharmacypharmacpharmacypharmMACROLIDE.pptxpharmacypharmacpharmacypharm
MACROLIDE.pptxpharmacypharmacpharmacypharm
 
CAL software Hemaharshini.G.pptxsdggfasf
CAL software Hemaharshini.G.pptxsdggfasfCAL software Hemaharshini.G.pptxsdggfasf
CAL software Hemaharshini.G.pptxsdggfasf
 
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
19.pptxgkckgdkfkdkgdlhsogdogsysgixjzgkxkxgixogx
 
37.Tidings (08.01.2024-13.01.2024)19.pptx
37.Tidings (08.01.2024-13.01.2024)19.pptx37.Tidings (08.01.2024-13.01.2024)19.pptx
37.Tidings (08.01.2024-13.01.2024)19.pptx
 
38.Tidings (15.01.2024-20.01..2024).pptx
38.Tidings (15.01.2024-20.01..2024).pptx38.Tidings (15.01.2024-20.01..2024).pptx
38.Tidings (15.01.2024-20.01..2024).pptx
 
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdfb0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
b0165a1f-7e7f-4e99-974a-e6b635b4244e.pdf
 
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
1a3ff92e-9ead-4075-a661-f6e32e7ad0d2.pdf
 
PHYSICAL & CHEMICAL PROPERTIES.pptx
PHYSICAL & CHEMICAL PROPERTIES.pptxPHYSICAL & CHEMICAL PROPERTIES.pptx
PHYSICAL & CHEMICAL PROPERTIES.pptx
 
benzene derivatives.pptx
benzene derivatives.pptxbenzene derivatives.pptx
benzene derivatives.pptx
 
CYCLOALKANES.pptx
CYCLOALKANES.pptxCYCLOALKANES.pptx
CYCLOALKANES.pptx
 
sympathomimeticdrugsppt-210519082222.pdf
sympathomimeticdrugsppt-210519082222.pdfsympathomimeticdrugsppt-210519082222.pdf
sympathomimeticdrugsppt-210519082222.pdf
 
planttissueculturelaboratory-151212154641.pdf
planttissueculturelaboratory-151212154641.pdfplanttissueculturelaboratory-151212154641.pdf
planttissueculturelaboratory-151212154641.pdf
 
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
3fdc996c-5921-4ba1-aaed-ca6141c9ecd3.pdf
 
Claisen condensation.pptx
Claisen condensation.pptxClaisen condensation.pptx
Claisen condensation.pptx
 
degradation.pptx
degradation.pptxdegradation.pptx
degradation.pptx
 
Beckmann Rearrangement.pptx
Beckmann Rearrangement.pptxBeckmann Rearrangement.pptx
Beckmann Rearrangement.pptx
 
Schmidt Rearrangement.pptx
Schmidt Rearrangement.pptxSchmidt Rearrangement.pptx
Schmidt Rearrangement.pptx
 
basicrequirementfortissueculture-190102180201.pdf
basicrequirementfortissueculture-190102180201.pdfbasicrequirementfortissueculture-190102180201.pdf
basicrequirementfortissueculture-190102180201.pdf
 
orientation of benzene .pptx
orientation of benzene .pptxorientation of benzene .pptx
orientation of benzene .pptx
 
UNIT - I.pptx
UNIT - I.pptxUNIT - I.pptx
UNIT - I.pptx
 

Recently uploaded

Recently uploaded (20)

How to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POSHow to Manage Global Discount in Odoo 17 POS
How to Manage Global Discount in Odoo 17 POS
 
How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17How to Manage Call for Tendor in Odoo 17
How to Manage Call for Tendor in Odoo 17
 
Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)Accessible Digital Futures project (20/03/2024)
Accessible Digital Futures project (20/03/2024)
 
Wellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptxWellbeing inclusion and digital dystopias.pptx
Wellbeing inclusion and digital dystopias.pptx
 
OS-operating systems- ch05 (CPU Scheduling) ...
OS-operating systems- ch05 (CPU Scheduling) ...OS-operating systems- ch05 (CPU Scheduling) ...
OS-operating systems- ch05 (CPU Scheduling) ...
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
Economic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food AdditivesEconomic Importance Of Fungi In Food Additives
Economic Importance Of Fungi In Food Additives
 
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdfFICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
FICTIONAL SALESMAN/SALESMAN SNSW 2024.pdf
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Introduction to TechSoup’s Digital Marketing Services and Use Cases
Introduction to TechSoup’s Digital Marketing  Services and Use CasesIntroduction to TechSoup’s Digital Marketing  Services and Use Cases
Introduction to TechSoup’s Digital Marketing Services and Use Cases
 
How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17How to Add New Custom Addons Path in Odoo 17
How to Add New Custom Addons Path in Odoo 17
 
Our Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdfOur Environment Class 10 Science Notes pdf
Our Environment Class 10 Science Notes pdf
 
VAMOS CUIDAR DO NOSSO PLANETA! .
VAMOS CUIDAR DO NOSSO PLANETA!                    .VAMOS CUIDAR DO NOSSO PLANETA!                    .
VAMOS CUIDAR DO NOSSO PLANETA! .
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Model Attribute _rec_name in the Odoo 17
Model Attribute _rec_name in the Odoo 17Model Attribute _rec_name in the Odoo 17
Model Attribute _rec_name in the Odoo 17
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
PANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptxPANDITA RAMABAI- Indian political thought GENDER.pptx
PANDITA RAMABAI- Indian political thought GENDER.pptx
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
AIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.pptAIM of Education-Teachers Training-2024.ppt
AIM of Education-Teachers Training-2024.ppt
 

UNIT - II.pptx

  • 1. Prepared by Padmaja V Asst. Prof. FCP, SBMCH
  • 2.  Definition  Etiology  Types  Pathophysiology/pathogenesis  Signs and symptoms  Diagnosis  treatment
  • 3. HYPERTENSION  Definition - Hypertension refers to sustained elevation in systemic arterial blood pressure.  The elevation may be in either systolic or diastolic pressure, or in both.  A normal upper limit for an adult is 130–139/85–89 mmHg and any readings consistently above this are considered as hypertension.  Normal – 120/80mmHg.
  • 4. Types of hypertension  Primary or essential hypertension (90 %).  Secondary hypertension (10%) where there is an underlying cause, such as renal diseases or tumour of the adrenal medulla.  Malignant hypertension occurs in the younger age groups with renal and collagen diseases.  Isolated systolic hypertension mainly occurs when a combination of factors is seen in the elderly, and is due to increases in cardiac output, increased peripheral resistance and renal vascular resistance.
  • 5. ETIOLOGY  Although the cause or causes of primary hypertension is unknown, several risk factors have been identified for its development:  obesity  stress  cigarette smoking and alcohol consumption  excessive intake of sodium causing fluid retention  family history.
  • 6.  Secondary hypertension results from underlying causes such as:  renal diseases  Cushing’s syndrome  hypo/hyperthyroidism  oral contraceptives  excessive alcohol consumption  coarctation (narrowing) of the aorta.
  • 7.
  • 8. PATHPHYSIOLOGY OF PRIMARY HYPERTENSION  Primary hypertension results from a combination of genetic and environmental factors which have an effect on renal and vascular functions.  One of the possible causes of primary hypertension is a deficiency in the kidney’s ability to excrete sodium, which increases extracellular fluid volume and cardiac output, resulting in an increase in blood flow to the tissues.  The increased blood flow to the tissues results in arteriolar constriction and an increase in peripheral vascular resistance (PVR) and blood pressure
  • 10. PATHOPHYSIOLOGY OF SECONDARY HYPERTENSION  Secondary hypertension is caused by diseases of the organs resulting in a raised PVR and increased cardiac output.  In most cases, the focus is on kidney diseases or excessive levels of hormones such as aldosterone and cortisol.  These hormones stimulate the retention of sodium and water, resulting in increased blood volume and blood pressure.  Once the underlying cause is treated, such as with the removal of the diseased organ, the blood pressure returns to normal.
  • 11.
  • 12. MALIGNANT HYPERTENSION  This is a rapidly progressive hypertension where the diastolic pressure is in excess of 120 mmHg which can result in encephalopathy, cerebral oedema and loss of consciousness.  Malignant hypertension does not indicate that there is cellular injury, but because it is life-threatening, it is considered as an emergency.  If untreated, cerebral oedema and cerebral dysfunction occur, leading to death of the individual.  Malignant hypertension can cause a variety of complications, e.g. papilloedema, cardiac failure, cerebrovascular accident and retinopathy
  • 13. ISOLATED SYSTOLIC HYPERTENSION  This is caused by an increase in cardiac output or PVR and has a higher incidence in the elderly.  The rigidity of the vessels is often caused by atherosclerosis.  The ageing process leads to hardening of the arteries, increased PVR and decreased baroreceptor sensitivity.  In isolated systolic hypertension, the systolic blood pressure is over 140 mmHg and the diastolic pressure is less than 90 mmHg.  It is recognised as an important risk factor for cerebrovascular accident and cardiac failure, and thus should be treated as a medical emergency.
  • 15. TREATMENT  Non-pharmacological interventions  Advise the patient to restrict sodium intake  cessation of cigarette smoking and excessive alcohol consumption reduce their stress levels .  Exercise and maintenance of a healthy weight  Pharmacological interventions  Diuretics are prescribed to reduce fluid load, which leads to reduction in cardiac output, thus helping to reduce blood pressure.  Medications, e.g. beta-blockers, calcium channel blockers and angiotensin-converting enzyme (ACE) inhibitors, are indicted for the treatment of hypertension
  • 16. HEART FAILURE  Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood to meet the body’s needs for blood and oxygen.  Basically, the heart can’t keep up with its workload.
  • 17. ETIOLOGY  Heart failure may be caused by a variety of conditions:  acute MI, where there is a loss of myocardial muscle, which can lead to poor contraction  hypertension  valvular heart disease  inadequate emptying from the left ventricle due to poor contraction of the myocardium  anaemia resulting from reduced red blood cells.
  • 18.
  • 19.
  • 20.
  • 21. Left-sided heart failure  In left-sided or left ventricular (LV) heart failure, the left side of the heart does not pump the blood sufficiently or work harder to pump the same amount of blood.  There are two types of left-sided heart failure.  Heart failure with reduced ejection fraction (HFrEF), also called systolic failure: The left ventricle loses its ability to contract normally. The heart can't pump with enough force to push enough blood into circulation.
  • 22.  Heart failure with preserved ejection fraction (HFpEF), also called diastolic failure (or diastolic dysfunction): The left ventricle loses its ability to relax normally (because the muscle has become stiff). The heart can't properly fill with blood during the resting period between each beat.
  • 23. Right-sided heart failure  Right-sided or right ventricular (RV) heart failure usually occurs as a result of left-sided failure.  When the left ventricle fails, increased fluid pressure is, in effect, transferred back through the lungs, ultimately damaging the heart's right side.  When the right side loses pumping power, blood backs up in the body's veins.  This usually causes swelling or congestion in the legs, ankles and swelling within the abdomen such as the GI tract and liver
  • 24. Congestive heart failure  Blood flow out of the heart slows, blood returning to the heart through the veins backs up, causing congestion in the body's tissues.  Often swelling (edema) results. Most often there's swelling in the legs and ankles.  Fluid collects in the lungs and interferes with breathing, causing shortness of breath, especially when a person is lying down. This is called pulmonary edema and if left untreated can cause respiratory distress.
  • 25. Pathophysiology  The onset of HF may be acute or chronic. It is often associated with systolic and diastolic congestion and with myocardial weakness.  This weakness impairs the ability of the heart to pump efficiently.  In acute HF, there is a sudden decrease in the amount of blood pumped out from both ventricles, which leads to a reduction in oxygen supply to the tissues.  However, in chronic HF the progression of the disease is gradual and in the early stages there may be no symptoms of heart failure.
  • 26. Pathophysiology of right heart failure  RHF is associated with the right ventricle being unable to pump the blood into the pulmonary artery leading into the lungs.  This leads to an increase in volume of the right ventricle during the end-diastolic phase, which causes an increase in volume of the right atria.  This in turn increases the volume of blood and pressure in the systemic venous system.  There is accumulation of blood in some of the major organs – the liver, the kidneys and the spleen, resulting in enlargement of these organs and their eventual destruction.
  • 27. Pathophysiology of left heart failure  LHF results from damage to the left ventricular myocardium.  The contraction of the left ventricle is ineffective and it cannot pump out all the blood it receives from the left atrium  This results in pooling of blood in the left atrium and raised pressure in the pulmonary veins, which leads to pulmonary oedema.  Failure of the left ventricle also results in poor cardiac output. As the cardiac output decreases, perfusion to the tissues also diminishes, resulting in poor delivery of oxygen and nutrients to the tissues
  • 28.
  • 29.
  • 31. TREATMENT  Non-pharmacological  Moderate physical activity  Weight reduction  Reduction in salt intake  Pharmacological
  • 32.
  • 33.
  • 34.
  • 35. ANGINA  Definition - Angina is chest pain that occurs when the heart muscle does not receive enough oxygenated blood.  It is also described as a crushing pain in the chest.  The term is derived from a Latin word meaning to choke.  The pain can radiate through to the back and shoulder, or down one or both arms, or into the neck and jaw.
  • 36. TYPES OF ANGINA  There are three types of angina:  1. stable angina  2. unstable angina  3. variant angina.
  • 37. STABLE ANGINA  Stable angina is the most common type and it occurs when there is a greater demand on the heart than usual.  Stable angina is mainly caused by myocardial ischemia.  The pain usually lasts about 3–5 minutes. If the blood flow is restored by immediate treatment, no permanent damage results
  • 38. UNSTABLE ANGINA  Unstable angina (also known as crescendo angina) is characterised by a change in frequency, intensity and duration of pain.  It is more serious than stable angina and is unpredictable.  It can also occur when the person is at rest and is not relieved by rest or medication.  Patients who develop unstable angina are at risk of having an MI
  • 39. VARIANT ANGINA  Variant angina is a rare form of angina.  It is thought to occur as a result of coronary artery vasospasm resulting in diminished blood flow.  Variant angina is very painful and occurs from midnight to early morning.  It usually occurs at rest and the same time each day
  • 40.
  • 41. PATHOPHYSIOLOGY  Angina results from a blockage in the coronary arteries, which reduces blood supply to the affected part of the heart muscle.  At rest the blood supply may be sufficient to provide nutrients and oxygen to the heart muscle; however, during activity, e.g. walking or running, the heart rate increases which puts more effort on the heart.  During exertion, if the blood flow to the heart muscle is inadequate, the oxygen supply is also diminished, leading to severe pain
  • 42.
  • 44. TREATMENT  Non-pharmacological interventions  eat a healthy diet and avoid saturated fat  encouraged to lose weight  Avoid excessive alcohol and smoking  blood pressure monitored regularly  Pharmacological interventions  GTN  Aspirin  Beta-blocker drugs  Statin drugs
  • 45. Myocardial infarction  Myocardial infarction (MI) is commonly referred to as a ’heart attack’, which results from oxygen starvation of the myocardium.  When the coronary blood flow is occluded as a result of a blood clot or fatty deposits (atheromatous plaque) over a period of time, death of the myocardium will take place, resulting in MI
  • 46. ETIOLOGY  Abnormal lipid profile  Diabetes mellitus  Psychosocial factors such as depression, loss of control, global stress, financial stress, and life events including marital separation, job loss, and family conflicts  Lack of physical activity
  • 47.
  • 48. PATHOPHYSIOLOGY  An occluded coronary artery results in myocardial ischaemia due to a lack of oxygen to the myocardial cells.  If the heart tissue is deprived of oxygen for a prolonged period of time, approximately 20–45 minutes, this can lead to cell death (necrosis) distal to the occlusion.  Damaged heart tissue conducts electrical signals much more slowly than normal heart tissue, which can result in inefficient contraction of the myocardium.
  • 49.  This can result in decrease:  volume of blood ejected by the left ventricle with each heartbeat  cardiac output (volume of blood pumped out by the left ventricle each minute)  blood pressure  tissue perfusion.
  • 50.
  • 51.
  • 52. Evaluation  The three components in the evaluation of the MI are  clinical features,  ECG findings, and  cardiac biomarkers
  • 54. TREATMENT  Non Pharmacological  Counseling and education of patients  Smoking cessation and avoid alcohol intake  Dietary control (low cholesterol)  Exercise  Weight reduction
  • 55.
  • 56. ATHEROSCLEROSIS/ARTERIOSCLEROSIS  Arteriosclerosis is the term describing arterial disorders in which degenerative changes result in decreased blood flow.  Atherosclerosis is the most common form of arteriosclerosis where there is thickening and hardening of the vessel walls due to lipid accumulation.  This condition is found mainly in the large- and medium- sized arteries, such as the aorta and its branches, the coronary arteries and the arteries that supply the brain, whereas arteriosclerosis mainly affects arterioles
  • 57. ETIOLOGY  The cause of atherosclerosis is not known, but certain risk factors have been identified:  Hypertension  cigarette smoking (nicotine has a vasoconstricting eff ect)  high lipid levels in the blood  familial history  obesity  diabetes mellitus (high serum glucose levels cause vascular damage)  lifestyle  alcohol  gender (men are at a higher risk than women).
  • 58.
  • 59. PATHOPHYSIOLOGY  Atherosclerosis is a form of arteriosclerosis where the walls of the arteries are hard, thick and narrow as a result of lipid accumulation within the arterial walls.  Lipids (low-density lipoproteins [LDL]) are deposited on the tunica intima of the damaged blood vessel where oxidation of LDL takes place.  The oxidised LDL then enters the tunica intima of the arterial wall, where they are ingested by macrophages.  The lipid-filled macrophages then become foam cells.
  • 60.  Once the foam cells accumulate in significant numbers, they form a lesion called a fatty streak, which over time causes a bulge in the lumen of the blood vessel and this restricts blood flow.  Affected blood vessels become hard, lose their elasticity, restrict blood flow and eventually occlude the artery.  Greater blood pressure is needed to push the blood through these narrow blood vessels, which leads to hypertension.  Although atherosclerosis can affect any organ or tissue, the arteries supplying the heart, brain, small intestines, kidneys and lower extremities are mostly affected.
  • 61.
  • 62.
  • 63.
  • 64.
  • 65. BRONCHIAL ASTHMA  Asthma is a disease of airways that is characterised by increased responsiveness of the tracheobronchial tree to a variety of stimuli resulting in widespread spasmodic narrowing of the air passages which may be relieved spontaneously or by therapy.  Asthma is an episodic disease manifested clinically by paroxysms of dyspnoea, cough and wheezing.  Asthma is a chronic inflammatory disorder of the lungs
  • 66.
  • 67.
  • 68.
  • 69.
  • 70. ETIOPATHOGENESIS AND TYPES  Two broad etiologic types are traditionally described:  extrinsic (allergic, atopic) asthma and  intrinsic (idiosyncratic, non-atopic) asthma
  • 71. 1. EXTRINSIC (ATOPIC, ALLERGIC) ASTHMA  In extrinsic asthma, airway inflammation is a consequence of hypersensitive reactions associated with allergy, i.e. pollen, dust mites or foodstuffs  It usually begins in childhood or in early adult life.  Most patients of this type of asthma have personal and/or family history of preceding allergic diseases such as rhinitis, urticaria or infantile eczema.  Hyper sensitivity to various extrinsic antigenic substances or ‘allergens’ is usually present in these cases.
  • 72.  Most of these allergens cause ill effects by inhalation e.g. house dust, pollens, animal danders, moulds etc.  Occupational asthma stimulated by fumes, gases and organic and chemical dusts is a variant of extrinsic asthma.  There is increased level of IgE in the serum and positive skin test with the specific off ending inhaled antigen representing an IgE-mediated type I hypersensitivity reaction which includes an ‘acute immediate response’ and a ‘late phase reaction’
  • 73.  Acute immediate response is initiated by IgE-sensitised mast cells (tissue counterparts of circulating basophils) on the mucosal surface.  Mast cells on degranulation release mediators like histamine, leukotrienes, prostaglandins, platelet activating factor and chemotactic factors for eosinophils and neutrophils.  The net effects of these mediators are bronchoconstriction, oedema, mucus hypersecretion and accumulation of eosinophils and neutrophils
  • 74.  Late phase reaction follows the acute immediate response and is responsible for the prolonged manifestations of asthma.  It is caused by excessive mobilisation of blood leucocytes that include basophils besides eosinophils and neutrophils.  These result in further release of mediators which accentuate the above-mentioned effects.
  • 75.  2. Intrinsic (idiosyncratic, non-atopic) asthma  Intrinsic asthma is linked to hyper-responsive reactions to other forms of stimuli, e.g. infection, sudden exposure to cold, exercise, stress or cigarette smoke  This type of asthma develops later in adult life with negative personal or family history of allergy, negative skin test and normal serum levels of IgE.  Most of these patients develop typical symptom complex after an upper respiratory tract infection by viruses.  Associated nasal polypi and chronic bronchitis are commonly present.  There are no recognisable allergens but about 10% of patients become hypersensitive to drugs, most notably to small doses of aspirin (aspirin-sensitive asthma).
  • 76. Pathophysiology  The bronchi and bronchioles contain smooth muscle and are lined with mucous-secreting glands and ciliated cells.  Close to the airway’s blood supply, there are large quantities of mast cells.  Once stimulated, mast cells release a number of cytokines (chemical messengers), which cause physiological changes to the lining of the bronchi and bronchioles.  Three such cytokines are histamine, kinins and prostaglandins, which cause smooth muscle contraction, increased mucus production and increased capillary permeability.
  • 77.  The airways soon narrow and become flooded with mucus and fluid leaking from blood vessels  As the airways become obstructed, the patient finds it increasingly hard to breathe and to cough up the mucus.  If unresolved, fatigue can occur and the patient’s respiratory effort becomes weak and inadequate, causing hypoxaemia and in severe cases, hypercapnia.
  • 78.
  • 79.
  • 83. COPD  Chronic Obstructive Pulmonary Disease (COPD)  Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs.  Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing.  Obstructive bronchiolitis is a condition in which chronic inflammation and swelling cause the inside of the breathing tubes (airways) to be smaller than normal.
  • 84.
  • 85.  Chronic bronchitis  Chronic bronchitis irritates your bronchial tubes, which carry air to and from your lungs. In response, the tubes swell and mucus (phlegm or “snot”) builds up along the lining.  The buildup narrows the tube’s opening, making it hard to get air into and out of your lungs.
  • 86.  EMPHYSEMA  This results from damage to your lungs’ air sacs (alveoli) that destroys the walls inside them and causes them to merge into one giant air sac. It can’t absorb oxygen as well, so you get less oxygen in your blood. Damaged alveoli can make your lungs stretch out and lose their springiness. Air gets trapped in your lungs and you can’t breathe it out, so you feel short of breath.
  • 87.
  • 88.
  • 89.
  • 90.
  • 91.
  • 92.
  • 93.
  • 94.
  • 95.
  • 96. ACUTE RENAL FAILURE  DEFINITION - Acute kidney injury (AKI), previously known as acute renal failure (ARF), is a condition in which the kidneys are unable to remove accumulated metabolites from the blood, leading to altered fluid, electrolyte and acid–base balance.  i.e acute fall in GFR, thus decreasing the clearance of metabolic waste products.
  • 97. TYPES 1.Prerenal  Prerenal causes include insufficient blood flow to the kidneys, resulting in reduced cardiac output as a result of heart failure, hypovolemia resulting from haemorrhage and shock.  The kidneys receive 20–25% of cardiac output to maintain glomerular filtration.  With a reduction in renal blood flow, glomerular filtration is affected and this causes ischaemic changes to the renal tissues.
  • 98. 2. Intrarenal  Intrarenal failure results from conditions that impair renal function.  The renal parenchyma and nephrons are damaged, leading to renal failure.  Glomerulonephritis, hypertension, chemicals such as ethyl glycol and drugs, e.g. antibiotics, can all affect renal function.  The nephrons of the kidneys are susceptible to trauma from poor renal blood flow, hypertension and shock.
  • 99.  The cell membranes of the nephrons are damaged as a result of the trauma.  The renal tubules become blocked with debris, thus increasing tubular pressure, resulting in poor elimination of sodium, water and metabolic waste.  Nephrotoxic drugs such as aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs and toxins from bacteria destroy tubular cells.  The damaged tubular cells become permeable to water, sodium and metabolic waste.
  • 100.  Post renal  Post renal failure results from obstruction along the ureters, urinary bladder and urethra.  Obstruction resulting from stones in the ureters, prostatic hyperplasia and urethral stricture could restrict urine flow, leading to postrenal failure.
  • 101.
  • 102.
  • 103.
  • 104.
  • 105. SIGNS AND SYMPTOMS  Edema in lower extremities  Uremic encephalopathy  Ascites  Mental confusion, restlessness  Poor skin turgidity  Postural hypotension
  • 106.
  • 107.
  • 108.
  • 109.
  • 110. CHRONIC RENAL FAILURE  DEFINITION - ) CRF is defined as the progressive reduction in renal function over months to years.  The condition is irreversible and eventually affects all the organs of the body.  The parenchyma and the nephrons are destroyed and the renal function progressively diminishes.
  • 111.  Etiology  There are many causes for CKD  renal disease such as polycystic disease  arteriosclerosis  chronic glomerulonephritis  chronic pyelonephritis  tuberculosis of the kidneys  diabetes nephropathy  hypertension  renal calculi  prostatic hypertrophy.